ECLATCD45RC Expression on T Lymphocytes as Acute Rejection Predictor in Renal Transplantation

Chronic renal failure is a significant health issue, affecting millions of people worldwide. Renal transplantation is the best treatment option for end-stage renal failure, offering improved patient survival compared to other treatments. However, a common challenge is allograft rejection, which occurs in 15% to 25% of cases within the first year and can lower the survival rate of the transplanted kidney. While certain risk factors like the recipient's young age or a high number of human leukocyte antigen (HLA) incompatibilities have been identified, they do not accurately predict the risk of acute rejection. This study aims to find reliable biomarkers that can predict allograft tolerance before transplantation, a major goal in renal transplantation. Researchers have found that the level of expression of a molecule called CD45RC on T lymphocytes (a type of white blood cell) is associated with an increased risk of acute rejection. This study seeks to confirm these initial findings in a larger, more contemporary regional group of patients. In this study, participants will undergo regular check-ups and monitoring. The primary focus is to measure the number of patients who develop acute rejection, which will be confirmed through an anatomopathological analysis of a graft biopsy. This involves examining a small sample of tissue from the transplanted kidney under a microscope. The study aims to understand the role of CD45RC expression in predicting acute rejection, which could potentially lead to improved and more personalized immunosuppressive strategies for renal transplant patients.